Dominique Hussey comments in Bloomberg BNA on draft changes to Canada's patent litigation process for prescription drugs. She points out that the changes create new opportunities and challenges, introduce complexity into the litigation and will raise new procedural and substantive issues that have no precedent. The amendments could take effect as early as September 21, 2017, when the Comprehensive Economic Trade Agreement (CETA) that inspired the changes will be provisionally applied.
In The News
Dominique Hussey in Bloomberg on Canada's Pharmaceutical IP Rules
July 26, 2017
Republication Requests
To obtain permission to republish this publication or any other publication, contact Erica Wirthlin at wirthline@bennettjones.com.
For Informational Purposes Only
This publication provides an overview of trends and legal updates for informational purposes only. For personalized legal advice, please contact the authors.
From the Same Authors
See AllArticle
WTR: Trademark Litigation Review 2024
December 12, 2023Dominique T. Hussey & Melissa M. Dimilta
Article
Winning Strategies for Litigating Before Canadian Courts
November 24, 2023Dominique T. Hussey & Melissa M. Dimilta
Latest Insights
See All Insights See AllBlog
Ontario Court Reinforces Finality of Class Proceedings in Rejecting Late Opt-Out Request
July 17, 2026Ethan Z. Schiff & Evana Yukanna
Blog
No Standing Without Specifics: Alberta Court of Appeal Confirms that Cumulative Effects are no Substitute for Evidence
July 16, 2026Martin Ignasiak KC, Tyler McDonough & Logan Lazurko
Blog
C$10 Million Capital Gains Exemption Made Permanent for Employee Ownership Trusts
July 14, 2026 & 1 more
















